stockrow
Saturday 7 November 2026
Export NVAX’s income statement to Excel — free account
Novavax, Inc.
NVAX Healthcare Biotechnology
Novavax, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 64.7% from fiscal 2024.
- Revenue
- −3.05%
- EPS
- +84.8%
- Free cash flow
- −189.1%
- Total debt
- +31.5%
Quarter to September 2026, against a year earlier
10.78
1.00
+10.22%
Follow NVAX
Alert me
Novavax, Inc. (NVAX) P/E ratio
Novavax, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 4.5× (October 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 2.5× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 2.5× | (40.03%) |
| 43 more quarters | Free account |
Against its own ten years
Low 0.0×
High 4.5×
Ten-year median
0.0×
Current reading's percentile
92
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ABSI Absci Corporation compare | n/m |
| SLS SELLAS Life Sciences Group, Inc. compare | n/m |
| GENB Generate Biomedicines, Inc. compare | n/m |
| KLRA Kailera Therapeutics, Inc. compare | n/m |
| NTLA Intellia Therapeutics, Inc. compare | n/m |
| NVAX Novavax, Inc. | n/m |
| NRIX Nurix Therapeutics, Inc. compare | 6.1× |
| BRVE Braveheart Bio, Inc. compare | — |
| LYCA Lycia Therapeutics Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)